Is Structure Therapeutics Inc. (GPCR) a Buy, Sell, or Hold?
Structure Therapeutics Inc.
NASDAQ:GPCR
$48.73 USD
-$1.86 (-3.68%)
- Volume
- 396.82K
- Average Volume
- 825.29K
- Market Capitalization
- $2.81B
- P/E Ratio
- -18.46
- Dividend Yield
- 0.00%
- Price Target
- $102.00
- Year High
- $94.90
- Year Low
- $15.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $26.16
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Raymond C. Stevens |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GPCR |
| CUSIP | 86366E106 |
| CIK | 0001888886 |
| Web | https://structuretx.com |
| Phone | 628-229-9277 |
| Currency | USD |
| Employees | 233 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 26.16 |
| Quick Ratio | 26.16 |
| Cash Ratio | 5.55 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.20 |
| Price / Cash Flow | -17.62 |
| Price / Book | 2.44 |
Price Target and Rating
| Average Stock Price Forecast | $102.00 |
| High Stock Price Forecast | $145.00 |
| Low Stock Price Forecast | $70.00 |
| Forecast Upside/Downside | -52.23% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.4 |
| Trailing P/E Ratio | -18.46 |
| PEG Ratio | 0.91 |
| P/E Growth | 0.91 |
| Net Income | $-141.2M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -15.14% |
| Return on Assets | -11.31% |
Financials Score
| AltmanZ Score | 29.49 |
| Piotroski Score | 2.00 |
| Working Capital | 1.43B |
| Total Assets | 1.51B |
| Ebit | -169.96M |
| Market Cap | 2.97B |
| Total Liabilities | 61.03M |
Poll Results
About Structure Therapeutics Inc. (NASDAQ:GPCR) Stock
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the a ... pelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
The Next Phase Of The Obesity Drug Race
2026-06-13 14:00:05
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Pharma are trying to fight for market share.
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)
2026-06-11 13:03:17
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway through 2028 underpin its ability to execute pivotal trials and commercial plans. My SOTP analysis yields a fair value of $42.49/share, with aleniglipron's risk-adjusted NPV at $1.34B and pipeline assets included at no additional cost.
2026-06-09 12:52:10
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure's experimental obesity pill shows no signs of liver injury
2026-06-05 17:16:43
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the drug.
2026-06-05 16:05:00
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
2026-05-26 16:05:00
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:
If Viking Therapeutics Is Acquired, Here’s Who Wins
2026-05-26 08:50:16
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
2026-05-24 10:19:48
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Frequently Asked Questions
-
What is the current Structure Therapeutics Inc. (GPCR) stock price?
-
Structure Therapeutics Inc.(NASDAQ:GPCR) stock price is $48.73 in the last trading session. During the trading session, GPCR stock reached the peak price of $94.9 while $15.8 was the lowest point it dropped to. The percentage change in GPCR stock occurred in the recent session was --3.68% while the dollar amount for the price change in GPCR stock was -$-1.86.
-
GPCR's industry and sector of operation?
-
The NASDAQ listed GPCR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GPCR?
-
Matthew Lang | COO & General Counsel
Hui Lei | Senior Vice President of Chemistry
Fang Zhang | Executive Vice President & Head of Biology
Blai Coll | Chief Medical Officer
Xichen Lin | Chief Scientific Officer & GM of Structure Shanghai -
How many employees does GPCR have?
-
Number of GPCR employees currently stands at 233. GPCR operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
Link for GPCR official website?
-
Official Website of GPCR is: https://structuretx.com
-
How do I contact GPCR?
-
GPCR could be contacted at phone #628-229-9277 and can also be accessed through its website. GPCR operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
How many shares of GPCR are traded daily?
-
The average number of GPCR shares traded daily for last 3 months was 825.29K.
-
What is the market cap of GPCR currently?
-
The market value of GPCR currently stands at $2.81B with its latest stock price at $48.73